Medical Device Capital Weekly Report - Issue 1

May 27, 2026 08:44 CST Updated 08:44

Medtronic

Medical Device Manufacturer

SPR Therapeutics

Peripheral Nerve Stimulation (PNS) Product Developer

Siemens Healthineers

Integrated Healthcare Service Provider

Sinzen Medtech

Minimally Invasive Treatment Technology Developer

Vortex Imaging

Ultrasound Imaging Technology Developer

Medical Devices · Capital Dynamics Weekly Report

May 18 – 22, 2026

I. Major Business Developments of Leading Global Medical Device Companies

`Time`	`Company`	Type	Event Summary	Impact Analysis
05-20	Medtronic	Strategic Acquisition	Announces Acquisition of SPR Therapeutics, with $650 Million Upfront Cash Payment, to Enhance Neuromodulation Pain Therapy Portfolio	Year-to-date cumulative M&A reached RMB 12.8 billion, with resources concentrated on three high-growth sectors: cardiovascular / neurointerventional / neuromodulation.
05-22	MicroPort	`Financing`	The Export-Import Bank of China, Shanghai Branch Issues Medium- and Long-Term Overseas Investment Loans to Support Overseas Operations and Core Technology R&D	Policy-Based Finance Facilitates Global Expansion of Industry Leaders, Easing Overseas Funding Pressures
05-19	Boston Scientific	Strategic Layout	"A3 International Medical Technology Innovation and Exchange Center," Spearheaded in Collaboration with Danaher and Siemens Healthineers, Officially Opens in Shanghai	Focusing on the Three Major Disease Areas of Cardiovascular and Cerebrovascular, Oncology, and Neuromodulation: Exploring a Disease-Centered Collaborative Innovation Model

II. Industry Investment and Financing Information

Time	Company	Sector	Round	Amount	Planning
05-19	Sinzen Medtech	Minimally Invasive Surgical Instruments	Series A	tens of millions of RMB	Zhirou® Suturing Device and Zhishui® Electrode have been commercialized, advancing the construction of the Anhui production base.
05-18	Vortex Imaging	3D Ultrasound Imaging	Funding Round	$12 million	Accelerating FDA Approval and Commercialization of Computational Ultrasound System
05-18	NVision	Quantum MRI Imaging	Series B	US$55 million	Expanding from Quantum Sensing to Quantum Computing Technology
05-18	Butterfly Medical	Benign Prostatic Hyperplasia	Series C	$21 million	Advancing Minimally Invasive BPH Implant Therapy, CE Certified
05-18	UroMems	Stress Urinary Incontinence	Strategic Investment	US$60 million	Large-Scale Clinical Trial of the UroActive Smart Artificial Urinary Sphincter

NVision Secures $55M Investment Led by Abbott to Expand Quantum MRI

III. Mergers & Acquisitions and Asset Restructuring News

Time	Acquirer	`Acquiree`	Transaction Scale	Direction	Significance
05-20	Medtronic	SPR Therapeutics	$650 million	Neuromodulation for Pain Management	Enhancing Peripheral Nerve Stimulation (PNS), Expanding Early Intervention for Chronic Pain
05-19	AP Technologies	Blueacre Technology	Not disclosed	Nitinol Catheter/Laser Processing	Vertically Integrated Catheter Platform and Establishment of European Operations Center in Ireland

IV. Capital Market IPO and Secondary Market Dynamics

4.1 IPO/Listing Application

Time	Company	`Segment`	Current Progress
05-22	Raytouch Robot	Hong Kong Stock Exchange	Receives CSRC Filing for Overseas Listing, Plans to Issue 45.941 Million Shares
05-22	Mingzhi Technology	Hong Kong Stock Exchange	CSRC Discloses Requirements for Supplementary Materials Regarding Equity Structure Compliance

4.2 Industry Market Capitalization and Stock Market Performance

Target	This Week's Data	Change
Deshi Biotech (02526.HK)	350 HKD (May 22 Close)	+13.78%

5. Industry Capital Trend Analysis and Market Perspectives

1. Investment and Financing Trends

This week's overseas medical device financing centered on urology and pelvic floor devices and diagnostic imaging, with NVision securing a $55 million investment led by Abbott to expand its quantum MRI technology, and UroMems raising $60 million to advance the clinical development of its smart artificial urinary sphincter; in China, minimally invasive surgical devices (Sinzen Medtech's Series A round) were the highlight.

2. M&A Integration Trends

On May 20, Medtronic announced a $650 million acquisition of SPR Therapeutics to bolster its neuromodulation portfolio, bringing its year-to-date M&A total to RMB 12.8 billion; AP Technologies acquired Blueacre to vertically integrate its catheter manufacturing supply chain.

3. Valuation and Market Sentiment

Desai surges 13.78% in a single day on the Hong Kong Stock Exchange after securing Class III certification for its AI large model, accelerating the commercialization of AI medical imaging; the IPO pipeline for surgical robots remains active (Ruichu Robotics completes filing); Chinese medical device companies continue to pursue the Hong Kong listing pathway.

4. Key Focus Areas

Quantum Sensing + MRI Integration (NVision/Abbott Collaboration)
Commercialization of AI Large Models for Medical Devices
M&A and Integration in the Neuromodulation Sector
Investment Interest in Urological and Pelvic Floor Devices

5. Risk Warning

⚠️ Compliance Risk:EUDAMED Mandatory Implementation on May 28: Non-Compliant Companies Face Market Exclusion Risk

⚠️ Price Pressure:Price Wars to Persist Under the Centralized Procurement "Anti-Involution" Mechanism

⚠️ Policy Adjustment:Smart Wearable Companies Must Adjust Business Models After New Medical Insurance Regulations Take Effect in September